NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care ...

Today’s positive decision follows the manufacturer, Daiichi Sankyo, offering a fair price for the treatment that the National Institute for Health and Care Excellence (NICE) determined to be ...

Inequalities in cardiovascular disease (CVD) care have been found, which impact clinical outcomes: Gender inequalities exist in CVD care, specifically with LDL-C goal attainment where despite ...

Daiichi Sankyo has identified inequalities in cardiovascular disease treatment and outcomes, finding that women in Europe are less likely than men to receive lipid-lowering therapies and achieve ...

European stocks erased early gains and were trading in the red by Tuesday lunchtime as investors adopted a cautious approach ahead of the European Central Bank policy meeting later in the week.

MUNICH, August 31, 2024--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) ...

2 Daiichi Sankyo committed to ETNA-AF, which combines data from distinct non-interventional studies in Europe, East Asia, and Japan in a single database, to delve deeper into the global burden of CVD.

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for ... It is also under review in Europe for both indications. The new BLA is based on the results of the TROPION-Breast01 trial, which ...